Eli Lilly Market Cap Tops $1.3 Trillion for First Time as Q3 Revenue Jumps 39%, Full-Year Guidance Raised

Eli Lilly's market cap hit $1.3T for the first time after Q3 revenue rose 39% YoY to $24.4B, net profit up 16% to $6.45B. The company raised full-year 2026 revenue guidance to $91B-$92B. Shares surged 7.19% to $1,380.95.

Original reporting
Published Oct 29, 2026, 3:55 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 4:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$LLY
Bullish
high confidence
Mentioned
$LLY
Relevance
8/10
AlphAI data visualization · based on finance.biggo.com
Decision brief

The 30-second read

$LLYBullishHigh
01

Why it matters

Lilly's earnings beat and guidance lift drove a 7% intraday rally, marking the first pharma firm to top $1.3T market cap.

02

Market read

A large‑cap pharma stock outperformed a tech‑driven market, highlighting sector rotation potential.

03

What to watch

Potential regulatory scrutiny on weight‑loss drugs and competitive pipeline could temper long‑term upside.

Relevance 8/10Novelty 9/10Timing: today

Background

The article reports Eli Lilly's Q3 earnings and guidance raise, contrasting it with tech sector weakness.

Company-level read

Ticker impact

$LLYBullishHigh confidence
Context

Eli Lilly reported Q3 revenue up 39% YoY and raised full-year 2026 revenue guidance to $91‑$92B, driving a 7.2% share surge.

Expected impact

likely continued upward pressure as investors price in higher revenue outlook

Evidence & confidence

The earnings beat and guidance lift are fresh, material, and moved the stock 7% intraday, indicating strong buying interest.

Market effects

Pharma sector may see valuation uplift as Lilly's milestone shows demand for weight‑loss/metabolic drugs.

U.S. market sees a rare large‑cap pharma rally amid broader tech weakness.

Lilly's market‑cap breach underscores diversification away from AI‑heavy tech stocks.

Counterpoint

If guidance proves unsustainable, the stock could face a pull‑back after the initial euphoria.

Key entities

  • Eli Lilly

    Pharmaceutical giant reporting Q3 results and guidance raise.

Related articles

$NVOLow

GLP-1 vision warning: Could demand be affected?

The FDA requires GLP-1 drugs to carry warnings about a potential increased risk of NAION, a condition that can cause vision loss. Analysis showed 6.4 cases per 100,000 person-years among users, though no causal link has been established. Experts believe the warnings will have limited impact on demand. Novo Nordisk and Eli Lilly, manufacturers of GLP-1 drugs, responded to the FDA's requirements, emphasizing patient safety and the lack of specific findings related to their medicines.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$LLYMed

ACR: Retatrutide Beneficial in Adults With Painful Knee OA, Obesity

A study published in the New England Journal of Medicine found that retatrutide, developed by Eli Lilly, significantly reduced knee pain and body weight in adults with painful knee osteoarthritis and obesity compared to placebo. The trials showed mean WOMAC pain score reductions of -3.96 and -3.74 for 9mg and 12mg doses, respectively, versus -2.12 for placebo, and weight reductions of -20.0% and -23.7% versus -4.6%. Serious adverse events were more common with retatrutide.

$LLYMed

Health Canada approves Eli Lilly’s daily Foundayo pill for weight loss

Health Canada approved Eli Lilly's daily oral weight-loss pill, Foundayo, for adults with obesity or related conditions. The drug, expected in January, competes with Lilly's injectables and Novo Nordisk's Rybelsus. Foundayo offers meal flexibility and differs chemically from other GLP-1 drugs. Pricing and insurance coverage will impact patient choices, with clinical trials showing varying weight-loss results.

$NVOHigh

What to know about the new GLP-1 pills now on sale

Novo Nordisk's Wegovy and Lilly's Foundayo, oral GLP-1 weight loss pills, are now available in Australia. Experts anticipate increased demand but caution about long-term effects and misuse. Prices range from $250 to $395 monthly, comparable to injectable versions. Availability varies by pharmacy.